Citations

Clear

4847 citation(s) found for "Tu, Eric".

Up-Regulation of Transient Receptor Potential Canonical 1 (TRPC1) following Sarco(endo)plasmic Reticulum Ca2+ATPase 2 Gene Silencing Promotes Cell Survival: A Potential Role for TRPC1 in Darier's Disease
Cornatzer, Eric, Cornatzer, W. E., Shin, Dong Min , Pittelkow, Mark R. , Hovnanian, Alain , Ambudkar, Indu S. , Singh, Brij B. , Pani, Biswaranjan , Hovnanian, Alain

Mayo Clinic

Molecular Biology of the Cell | August 10, 2006 | Volume: 17 | Issue: 10 | Pages: 4446-4458

10.1091/mbc.e06-03-0251 | PMID 16899508 Get It

The mechanism(s) involved in regulation of store operated calcium entry in Darier's disease (DD) is not known. We investigated the distribution and function of transient receptor potential canonical (TRPC) in epidermal skin cells. DD patients demonstrated up-regulation of TRPC1, but not TRPC3, in the squamous layers. Ca2+influx was significantly higher in keratinocytes obtained from DD patients and showed enhanced proliferation compared with normal keratinocytes. Similar up-regulation of TRPC1 was also detected in epidermal layers of SERCA2+/−mice. HaCaT cells expressed TRPC1 in the plasma membrane. Expression of sarco(endo)plasmic reticulum Ca2+ATPase (SERCA)2 small interfering RNA (siRNA) in HaCaT cells increased TRPC1 levels and thapsigargin-stimulated Ca2+influx, which was blocked by store-operated calcium entry inhibitors. Thapsigargin-stimulated intracellular Ca2+release was decreased in DD cells. DD keratinocytes exhibited increased cell survival upon thapsigargin treatment. Alternatively, overexpression of TRPC1 or SERCA2-siRNA in HaCaT cells demonstrated resistance to thapsigargin-induced apoptosis. These effects were dependent on external Ca2+and activation of nuclear factor-κB. Isotretinoin reduced Ca2+entry in HaCaT cells and decreased survival of HaCaT and DD keratinocytes. These findings put forward a novel consequence of compromised SERCA2 function in DD wherein up-regulation of TRPC1 augments cell proliferation and restrict apoptosis. We suggest that the anti-apoptotic effect of TRPC1 could potentially contribute to abnormal keratosis in DD.
Impact of Familial and Hereditary Prostate Cancer on Cancer Specific Survival After Radical Retropubic Prostatectomy
Siddiqui, Sameer , Sengupta, Shomik , Slezak, Jeffrey M., Bergstralh, Eric J., Zincke, Horst, Blute, Michael L.

Mayo Clinic

Journal of Urology | August 9, 2006 | Volume: 176 | Issue: 3 | Pages: 1118-1121

10.1016/j.juro.2006.04.077 | PMID 16890705 Get It

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
Bower, James H., Maraganore, Demetrius M. , Peterson, B. J., Ahlskog, J. Eric , Rocca, Walter A.

Mayo Clinic

Neurology | August 7, 2006 | Volume: 67 | Issue: 3 | Pages: 494-496

10.1212/01.wnl.0000227906.99570.cc | PMID 16894114 Get It

Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia
Weems, J. John, Steinberg, James P. , Corey, G. Ralph, Sampathkumar, Priya , Winston, Lisa G., John, Joseph F. , Kubin, Christine J. , Talwani, Rohit , Moore, Thomas , Patti, Joseph M., Hetherington, Seth, Texter, Michele, Wenzel, Eric, Kelley, Violet A., Fowler, Vance G. , Filler, Scott G. , Baddley, John W. , Fowler, Vance G.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | July 26, 2006 | Volume: 50 | Issue: 8 | Pages: 2751-2755

10.1128/aac.00096-06 | PMID 16870768 Get It

ABSTRACT Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious Staphylococcus aureus infections. Sixty patients with documented S. aureus bacteremia (SAB) were randomized and received either tefibazumab at 20 mg/kg of body weight as a single infusion or a placebo in addition to an antibiotic(s). The primary objective of the study was determining safety and pharmacokinetics. An additional objective was to assess activity by a composite clinical end point (CCE). Baseline characteristics were evenly matched between groups. Seventy percent of infections were healthcare associated, and 57% had an SAB-related complication at baseline. There were no differences between the treatment groups in overall adverse clinical events or alterations in laboratory values. Two patients developed serious adverse events that were at least possibly related to tefibazumab; one hypersensitivity reaction was considered definitely related. The tefibazumab plasma half-life was 18 days. Mean plasma levels were <100 μg/ml by day 14. A CCE occurred in six patients (four placebo and two tefibazumab patients) and included five deaths (four placebo and one tefibazumab patient). Progression in the severity of sepsis occurred in four placebo and no tefibazumab patients. Tefibazumab was well tolerated, with a safety profile similar to those of other monoclonal antibodies. Additional trials are warranted to address the dosing range and efficacy of tefibazumab.
High WT1 Expression Is Associated with Very Poor Survival of Patients with Osteogenic Sarcoma Metastasis
Srivastava, Alok , Fuchs, Bruno , Ruan, Ming, Halder, Chandralekha, Mahlum, Eric, Weber, Kristin L., Bolander, Mark E., Sarkar, Gobinda , Zhang, Kunbo

Mayo Clinic

Clinical Cancer Research | July 20, 2006 | Volume: 12 | Issue: 14 | Pages: 4237-4243

10.1158/1078-0432.ccr-05-2307 | PMID 16857797 Get It

Abstract Purpose: Although metastasis is the primary determinant of poor survival of patients with osteogenic sarcoma, some patients live much longer than others, indicating metastatic heterogeneity underlying survival outcome. The purpose of the investigation was to identify genes underlying survival outcome of patients with osteogenic sarcoma metastasis. Experimental Design: We have used microarray to first compare mRNA expression between normal bone and osteogenic sarcoma specimens, identified genes overexpressed in osteogenic sarcoma, and compared expression of the selected gene between a poorly metastatic (SAOS) and two highly metastatic cell lines (LM8 and 143B). Finally, expression of the selected gene was assessed by immunostaining of osteogenic sarcoma samples with known survival outcome. Results: Microarray analysis revealed 5.3-fold more expression of WT1 mRNA in osteogenic sarcoma compared with normal bone and &gt;2-fold overexpression in 143B and LM8 cells compared with SAOS. Furthermore, WT1 mRNA was absent in normal bone (10 of 10) by reverse transcription-PCR but present in osteogenic sarcoma–derived cell lines (5 of 8). One hundred percent (42 of 42) of low-grade osteogenic sarcoma specimens expressed no WT1 as determined by immunostaining; however, 24% (12 of 49) of the high-grade specimens showed intense staining. Mean survival of patients with high-grade metastatic osteogenic sarcoma but low WT1 staining (27 of 37) was 96.5 ± 129.3 months, whereas mean survival of patients with high-grade metastatic osteogenic sarcoma having intense staining (10 of 37) was 18.3 ± 12.3 months (P &gt; 0.0143). All splice variants of WT1 mRNA, including a hitherto unknown variant (lacking exons 4 and 5), were found to be expressed in osteogenic sarcoma. Conclusion: WT1 seems to be associated with very poor survival of patients with osteogenic sarcoma metastasis.
Tyrosines in the MUC1 Cytoplasmic Tail Modulate Transcription via the Extracellular Signal-Regulated Kinase 1/2 and Nuclear Factor-κB Pathways
Thompson, Eric J., Shanmugam, Kandavel , Hattrup, Christine L., Kotlarczyk, Kari, Gutierrez, Albert, Mukherjee, Pinku , Gendler, Sandra , Bradley, Judy Martina

Mayo Clinic

Molecular Cancer Research | July 18, 2006 | Volume: 4 | Issue: 7 | Pages: 489-497

10.1158/1541-7786.mcr-06-0038 | PMID 16849524 Get It

Abstract Much of the ability of the MUC1 oncoprotein to foster tumorigenesis and tumor progression likely originates from the interaction of its cytoplasmic tail with proteins involved in oncogenic signaling. Many of these interactions are regulated by phosphorylation, as the cytoplasmic tail contains seven highly conserved tyrosines and several serine/threonine phosphorylation sites. We have developed a cell line–based model system to study the effects of tyrosine phosphorylation on MUC1 signaling, with particular emphasis on its effects on gene transcription. COS-7 cells, which lack endogenous MUC1, were stably infected with wild-type MUC1 or a MUC1 construct lacking all seven tyrosines (MUC1 Y0) and analyzed for effects on transcription mediated by the extracellular signal-regulated kinase 1/2 (ERK1/2) and nuclear factor-κB (NF-κB) pathways. COS.MUC1 Y0 cells showed heightened active ERK1/2 with increased activator protein-1 (AP-1) and signal transducer and activator of transcription 3 (STAT3) transcriptional activity; there was also a simultaneous decrease in NF-κB transcriptional activity and nuclear localization. These changes altered the phenotype of COS.MUC1 Y0 cells, as this line displayed increased invasion and enhanced [3H]thymidine incorporation. Analysis of the three lines also showed significant differences in their cell cycle profile and bromodeoxyuridine incorporation when the cells were serum starved. These data support the growing evidence that MUC1 is involved in transcriptional regulation and link MUC1 for the first time to the NF-κB pathway. (Mol Cancer Res 2006;4(7):489–97)
Incidence of adaptive equipment use in subjects with a remote history of paralytic poliomyelitis
Sorenson, Eric J. , Windebank, Anthony J.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 65 | Issue: 6 | Pages: 963-963

10.1212/01.wnl.0000175986.79723.8e | PMID 16186550 Get It

Neurologic manifestations in welders with pallidal MRI T1 hyperintensity
Josephs, Keith A. , Ahlskog, J. Eric , Klos, Kevin J., Kumar, Neeraj , Fealey, Robert D., Trenerry, Max R., Cowl, Clayton T.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 64 | Issue: 12 | Pages: 2033-2039

10.1212/01.wnl.0000167411.93483.a1 | PMID 15888601 Get It

Role and Results of Surgery in Acute Type B Aortic Dissection
Trimarchi, Santi , Rampoldi, Vincenzo, Myrmel, Truls , Bossone, Eduardo , Tolva, Valerio , Deeb, Michael G., Cooper, Jeanna V., Fang, Jianming, Sundt, Thoralf M. , Nienaber, Christoph , Suzuki, Toru , Upchurch, Gilbert R. , Isselbacher, Eric M. , Eagle, Kim A. , Bossone, Eduardo

Mayo Clinic

Circulation | July 7, 2006 | Volume: 114 | Issue: 1_supplement | Pages: No page available

10.1161/circulationaha.105.000620 | PMID 16820600 Get It

Background— The clinical profiles and outcomes of patients treated surgically for acute type B aortic dissection (ABAD) are often reported for those in small series or for those cared for at a single institution over a long time period, during which a continuous evolution in techniques has occurred. Accordingly, we sought to evaluate the clinical features and surgical results of patients enrolled in the International Registry of Acute Aortic Dissection by identifying primary factors that influenced surgical outcome and estimating average surgical mortality for ABAD in the current era. Methods and Results— A comprehensive analysis of 290 clinical variables and their relation to surgical outcomes for 82 patients who required surgery for ABAD (from a population of 1256 patients; mean±SD age, 60.6±15.0 years; 82.9% male) and who were enrolled in the International Registry of Acute Aortic Dissection was performed. The overall in-hospital mortality was 29.3%. Factors associated with increased surgical mortality based on univariate analysis were preoperative coma or altered consciousness, partial thrombosis of the false lumen, evidence of periaortic hematoma on diagnostic imaging, descending aortic diameter >6 cm, right ventricle dysfunction at surgery, and shorter time from the onset of symptoms to surgery. Factors associated with favorable outcomes included radiating pain, normotension at surgery (systolic blood pressure 100 to 149 mm Hg), and reduced hypothermic circulatory arrest time. The 2 independent predictors of surgical mortality were age >70 years (odds ratio, 4.32; 95% confidence interval, 1.30 to 14.34) and preoperative shock/hypotension (odds ratio, 6.05; 95% confidence interval, 1.12 to 32.49). Conclusions— The present study provides insights into current-day clinical profiles and surgical outcomes of ABAD. Knowledge about different preoperative clinical conditions may help surgeons in making treatment decisions among these high-risk patients.